EuroTimes Satellite Education Programme

Friday 15 May 13.00 - 14.00
The Evidence Builds Up: New Lucentis Data to Help Maintain Patient Benefits in Clinical Practice

Venue: Clio/Thalie

Moderator - F. Bandello ITALY

	F. Bandello ITALY Current perspectives in the treatment of neovascular AMD
	W. Amoaku UK 12-month efficacy and safety update from the SUSTAIN Trial
	F. Holz GERMANY Analysis of patient response profiles: Using evidence from SUSTAIN and EXCITE to better predict treatment outcomes
	J.F. Korobelnik FRANCE Applying the data to clinical practice – lessons learned from clinical trials
	Panel discussion: Impact of recent data on the treatment of neovascular AMD
	F. Bandello ITALY Summary & closing remarks

Sponsored By:

Friday 15 May 13.00 - 14.00
Retinal Surgery – New Dimensions in Patient Safety

Venue: Erato

Moderator - J.P. Berrod FRANCE

	H. Kaymak GERMANY  Perfect mixture -  Siluron 2000: the new premium endotamponade, theory & application
	P. Müther GERMANY  Mission Infusion - The new infusion cannula with redirected flow
	M. Becker SWITZERLAND Extended view - Microscope data projection: possibilities & prospects

Sponsored By:

Friday 15 May 17.00 - 18.15
Role of Inflammation in Macular Edema

Venue: Apollon

Moderators - G. Coscas FRANCE, J. Cunha-Vaz PORTUGAL

	Introduction: Moderators
	W. Drexler UK In vivo imaging of ME
	J. Edelman USA Role of inflammation in ME - Animal models
	B. Kuppermann USA Steroids, are they all the same?
	A. Loewenstein ISRAEL Therapeutic options for DME, current evidence
	F. Bandello ITALY Management of ME, mono or combination treatment
	A. Loewenstein & Panel Future management of ME – a paradigm shift?
	Summary & closing remarks

Sponsored By:

Saturday 16 May 13.00 - 14.00
Access to the Future... Today

Venue: Clio/Thalie

Moderator - G. Williams USA

	G. Williams USA New advancements in vitreoretinal surgery
	S. Rizzo ITALY Clinical experience with Constellation
	J. Garcia-Arumi  SPAIN Working with 23G in retinal detachment
	J.F. Korobelnik FRANCE Clinical experience with the new Alcon 25+
	Panel Discussion
	G. Williams USA Conclusions

Sponsored By:

Saturday 16 May 13.00 - 14.00
Is VEGF Selectivity Important in the Management of Risk in the Wet AMD Patient? 

Venue: Hermes

Moderator - E. Midena ITALY

	Introduction
	J. Waltenberger THE NETHERLANDS The physiological roles of VEGF-A and its isoforms
	T. Friberg USA Results from the LEVEL study
	D. Boyer USA Clinical perspectives on the long-term use of anti-VEGF agents in wet AMD
	Panel discussion and audience questions Led by E. Midena, joined by faculty
	Summary and close

Sponsored By:

Saturday 16 May 13.00 - 14.00
Spectralis – New Insights in Retina 

Venue: Erato

Moderator - T.B.C.

	U. Wolf-Schnurrbusch SWITZERLAND Macular Thickness Measurements in Healthy Eyes Using Six Different OCT Instruments
	F. Holz GERMANY  Multimodal Imaging for Retinal Diagnosis
	T.B.C. Fundus Autofluorescence Imaging in Anti-VEGF Therapy

Sponsored By:

EUROTIMES UPDATE SESSION

Saturday 16 May 17.00 - 18.15
EuroTimes Update on Diabetic Retinopathy  

Venue: Clio/Thalie

Moderator - J. Cunha-Vaz PORTUGAL

Objectives:

• Review the current understanding of the complex cellular and molecular pathogenesis of
  diabetic retinopathy, especially the mechanisms responsible for edema formation and retinal neovascularisation
  
  
• Brief overview of current treatment for DR and treatments in development, in particular anti-VEGF
  
  
• Discuss the challenges and considerations for the treatment of diabetic patients

Scientific Programme:

	J. Cunha-Vaz PORTUGAL Introduction & welcome
	E. Midena ITALY Understanding the pathogenesis of diabetic macular edema and proliferative diabetic retinopathy
	M. Carvalheiro PORTUGAL Treating the diabetic patient
	Current and future perspective on the treatment of diabetic retinopathy: D. Boyer USA Focus on diabetic macular edema V. Gonzalez USA Focus on proliferative diabetic retinopathy
	J. Cunha-Vaz PORTUGAL Concluding remarks and close

(Supported by an unrestricted educational grant from Pfizer Ophthalmics)